- Home
- MGNX vs OKYO Comparison
MGNX vs OKYO Comparison
Compare MGNX & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- OKYO
- Stock Information
- Founded
- MGNX 2000
- OKYO 2007
- Country
- MGNX United States
- OKYO United Kingdom
- Employees
- MGNX N/A
- OKYO N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGNX Health Care
- OKYO Health Care
- Exchange
- MGNX Nasdaq
- OKYO Nasdaq
- Market Cap
- MGNX 99.7M
- OKYO 85.0M
- IPO Year
- MGNX 2013
- OKYO 2022
- Fundamental
- Price
- MGNX $1.53
- OKYO $2.13
- Analyst Decision
- MGNX Hold
- OKYO Strong Buy
- Analyst Count
- MGNX 6
- OKYO 1
- Target Price
- MGNX $3.20
- OKYO $7.00
- AVG Volume (30 Days)
- MGNX 1.0M
- OKYO 56.1K
- Earning Date
- MGNX 11-04-2025
- OKYO 07-18-2025
- Dividend Yield
- MGNX N/A
- OKYO N/A
- EPS Growth
- MGNX N/A
- OKYO N/A
- EPS
- MGNX N/A
- OKYO N/A
- Revenue
- MGNX $165,495,000.00
- OKYO N/A
- Revenue This Year
- MGNX N/A
- OKYO N/A
- Revenue Next Year
- MGNX N/A
- OKYO N/A
- P/E Ratio
- MGNX N/A
- OKYO N/A
- Revenue Growth
- MGNX 303.47
- OKYO N/A
- 52 Week Low
- MGNX $0.99
- OKYO $0.90
- 52 Week High
- MGNX $5.10
- OKYO $3.35
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- OKYO 36.03
- Support Level
- MGNX $1.46
- OKYO $2.07
- Resistance Level
- MGNX $1.77
- OKYO $2.39
- Average True Range (ATR)
- MGNX 0.15
- OKYO 0.14
- MACD
- MGNX -0.04
- OKYO -0.00
- Stochastic Oscillator
- MGNX 9.21
- OKYO 17.50
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.